CRIS
Curis, Inc.
There isn't enough reported data to score CRIS yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CRIS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
CRIS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CRIS PE Valuation
CRIS has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CRIS Forward outlook
There aren't enough analyst estimates for CRIS to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CRIS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.02 | +$92.58 |
| Q1 2026 | -$11.60 | +$110.00 |
| Q4 2025 | -$11.60 | +$126.00 |
| Q3 2025 | -$70.40 | +$85.80 |
| Q2 2025 | -$94.60 | +$70.20 |
| Q1 2025 | -$121.60 | +$50.60 |
| Q4 2024 | -$137.60 | +$41.60 |
| Q3 2024 | -$156.20 | +$30.40 |
CRIS has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CRIS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $1.1M | -66% |
| Q3 2025 | $3.2M | +8.4% |
| Q2 2025 | $2.7M | +8% |
| Q1 2025 | $2.4M | +14% |
| Q4 2024 | $3.3M | +24% |
| Q3 2024 | $2.9M | +3.5% |
| Q2 2024 | $2.5M | +16% |
| Q1 2024 | $2.1M | -9.2% |
CRIS's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 1724% | +1993 points |
| Q3 2025 | -218% | +143 points |
| Q2 2025 | -300% | +191 points |
| Q1 2025 | -427% | +171 points |
| Q4 2024 | -269% | +184 points |
| Q3 2024 | -361% | +76 points |
| Q2 2024 | -491% | +61 points |
| Q1 2024 | -598% | -92 points |
CRIS's operating margin was 1724% last quarter, up 1993 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CRIS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CRIS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.6M | -$1.6M |
| Q1 2026 | -$9M | -$1.7M |
| Q4 2025 | -$6.4M | +$2.9M |
| Q3 2025 | -$5.6M | +$367K |
| Q2 2025 | -$8M | +$3.1M |
| Q1 2025 | -$7.3M | +$6M |
| Q4 2024 | -$9.3M | +$926K |
| Q3 2024 | -$5.9M | +$2.2M |
CRIS has burned cash in almost every quarter: −$31M over the past year, against −$30M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CRIS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRIS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +121% | +1.2M shares |
| 1 year | +238% | +1.5M shares |
| 3 years | +784% | +1.9M shares |
| 5 years | +1187% | +2M shares |
| Available history | +2473% | +2.1M shares |
CRIS has 2M diluted shares, up 238% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CRIS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CRIS Net Leverage
CRIS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CRIS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.9 | Oversold |
| Stochastic | 7.6 | Oversold |
CRIS's weekly RSI is 24 (oversold) and its Stochastic is 8 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CRIS PE vs Healthcare Sector
CRIS has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CRIS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.65 | 12% below |
| 20 week MA | $2.20 | 74% below |
| 50 week MA | $10.3 | 94% below |
| 100 week MA | $26.8 | 98% below |
| 200 week MA | $118.4 | 100% below |
CRIS is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CRIS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $620.0 | $3,180.0 | +413% |
| 2021 | $3,180.0 | $2,072.0 | -35% |
| 2022 | $2,072.0 | $197.4 | -90% |
| 2023 | $197.4 | $255.0 | +29% |
| 2024 | $255.0 | $65.0 | -75% |
| 2025 | $65.0 | $21.2 | -67% |
| 2026 YTD | $21.2 | $0.57 | -97% |
CRIS's yearly returns have swung widely, from +413% in 2020 to −90% in 2022. It's down 97% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over CRIS on returns for 2026, with the stronger performance.